Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nyxoah (NASDAQ: NYXH) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2026. The presentation begins at 12:00 PM PT. A live audio webcast will be available on the company's investor relations website at investors.nyxoah.com.

This presentation offers investors a chance to hear management's update on Nyxoah's neuromodulation therapy for obstructive sleep apnea and company strategy directly from executives.

News Market Reaction – NYXH

-2.11% 3.3x vol

7 alerts

-2.11% News Effect

+3.3% Peak Tracked

-60.4% Trough Tracked

-$5M Valuation Impact

$209M Market Cap

3.3x Rel. Volume

On the day this news was published, NYXH declined 2.11%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -60.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $209M at that time. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference edition: 44th Annual J.P. Morgan Healthcare Conference Presentation time: 12:00 p.m. PT Current share price: $4.47 +1 more

4 metrics

Conference edition 44th Annual J.P. Morgan Healthcare Conference Event where Nyxoah management will present

Presentation time 12:00 p.m. PT Scheduled time of J.P. Morgan conference presentation on Jan. 15, 2026

Current share price $4.47 Price before J.P. Morgan conference announcement

Price vs 52-week high -62.34% Performance relative to $11.87 52-week high

Market Reality Check

Price: $3.15 Vol: Volume 19,859 is below th...

low vol

$3.15 Last Close

Volume Volume 19,859 is below the 20-day average of 30,119 (relative volume 0.66x) ahead of the conference update. low

Technical Shares at $4.47 are trading below the 200-day MA of $6.45, near the 52-week low of $4.345 and 62.34% under the $11.87 52-week high.

Peers on Argus

NYXH was down 3.87% while peers showed mixed moves (e.g., AVR up 2.57%, KRMD dow...

NYXH was down 3.87% while peers showed mixed moves (e.g., AVR up 2.57%, KRMD down 3.41%, others modestly positive/negative), pointing to more stock-specific trading rather than a clear sector trend.

Historical Context

5 past events · Latest: Dec 19 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 19	Convertible bond financing	Negative	-2.1%	First tranche of €22.5M convertible bonds with 6.5% coupon and 3-year term.
Dec 17	Product launch	Positive	+0.0%	Commercial launch of Genio bilateral neurostimulation system in the Netherlands.
Dec 02	Ownership disclosure	Neutral	-0.7%	Transparency notifications on voting-rights changes for a major shareholder.
Nov 27	Conference participation	Neutral	+2.8%	Participation in Piper Sandler healthcare conference with webcasted fireside chat.
Nov 20	Capital structure update	Neutral	+1.5%	Publication of updated share capital, voting rights, and subscription rights figures.

Pattern Detected

Recent news has often seen muted or contrary price reactions, with only the November conference participation aligning clearly with a positive move.

Recent Company History

Over the last six weeks, Nyxoah combined financing, corporate disclosures and commercial progress. A November 17 prospectus and subsequent multi-part financings, including convertible notes, expanded funding for Genio commercialization. November disclosures on total voting rights and later transparency notifications updated ownership and capital structure. Nyxoah also highlighted investor-relations activity via the Piper Sandler conference and announced the commercial launch of the Genio system in the Netherlands. Today’s J.P. Morgan conference appearance continues this pattern of investor-facing communication rather than a new clinical or regulatory milestone.

Market Pulse Summary

This announcement highlights Nyxoah’s upcoming presentation at the 44th J.P. Morgan Healthcare Confe...

Analysis

This announcement highlights Nyxoah’s upcoming presentation at the 44th J.P. Morgan Healthcare Conference, offering management another platform to discuss strategy and progress on its Obstructive Sleep Apnea neuromodulation therapies. In recent months, the company combined multiple financings with new commercial steps for its Genio system and several capital-structure disclosures. Investors may watch for messaging around use of recent proceeds, commercialization milestones, and any updated timelines or metrics discussed during the January 15, 2026 presentation.

Key Terms

obstructive sleep apnea, neuromodulation, webcast

3 terms

obstructive sleep apnea medical

"breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

neuromodulation medical

"breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

webcast technical

"A live audio webcast of the presentation will be available online"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

Nyxoah to Present at the 44^th Annual J.P. Morgan Healthcare Conference

Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.

A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contact:

Nyxoah
John Landry, CFO
IR@nyxoah.com

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
IR@nyxoah.com

Attachment

• ENGLISH_NYXH JP Morgan Conf Advisory PR_2025

FAQ

When will Nyxoah (NYXH) present at the J.P. Morgan Healthcare Conference?

Nyxoah will present on January 15, 2026 with the session starting at 12:00 PM PT.

How can investors watch Nyxoah's (NYXH) presentation at the J.P. Morgan Healthcare Conference?

A live audio webcast will be available on Nyxoah's investor relations page at investors.nyxoah.com.

What topics will Nyxoah (NYXH) management likely cover at the Jan. 15, 2026 presentation?

Management will provide updates on the company's neuromodulation treatment for obstructive sleep apnea and corporate strategy.

What time is Nyxoah's (NYXH) presentation in Eastern Time?

The presentation begins at 12:00 PM PT, which is 3:00 PM ET.

Where is the 44th Annual J.P. Morgan Healthcare Conference held for Nyxoah's (NYXH) presentation?

The conference takes place in San Francisco; Nyxoah's presentation will be at the event on Jan. 15, 2026.

Will Nyxoah (NYXH) provide a replay of the J.P. Morgan presentation?

A live audio webcast will be available; check Nyxoah's investor relations site for any replay or archived recording.